Bispecific Antibody Pumitamig Shows 70% Response Rate in Early NSCLC Trial Data

A new class of "bispecific" antibodies — engineered to block two different cancer-supporting biological pathways with a single molecule — continues to generate notable early results in non-small cell lung cancer (NSCLC).

Pumitamig (also known by the development code BNT327/BMS986545) targets both PD-L1, an immune checkpoint protein, and VEGF-A, a driver of tumor blood vessel growth. In the phase 2 dose-optimization portion of the global phase 2/3 ROSETTA Lung-02 trial, researchers tested pumitamig plus chemotherapy in 44 patients with advanced NSCLC who had no actionable genomic alterations and good baseline performance status. The combination produced a 70.0% overall response rate and a 100% disease control rate across the two dosing levels tested.

The rationale behind dual PD-L1/VEGF-A blockade is that tumor blood vessel growth and immune evasion can reinforce each other; blocking both simultaneously may overcome resistance mechanisms that limit single-pathway checkpoint inhibitors alone. Reported activity in this trial appeared independent of PD-L1 expression level, which — if confirmed in larger studies — could broaden the population of patients such an approach might eventually serve.

Bispecific and dual-pathway antibody programs are one of the more actively growing categories in current lung cancer drug development. Our Research Progress Tracker shows how this category compares, in trial volume, to more established categories like single-agent immunotherapy and targeted therapy.